147 related articles for article (PubMed ID: 2151565)
1. Plasminogen activation at the cell surface-matrix interface.
Vaheri A; Stephens RW; Salonen EM; Pöllänen J; Tapiovaara H
Cell Differ Dev; 1990 Dec; 32(3):255-62. PubMed ID: 2151565
[No Abstract] [Full Text] [Related]
2. The urokinase receptor and regulation of cell surface plasminogen activation.
Blasi F; Behrendt N; Cubellis MV; Ellis V; Lund LR; Masucci MT; Møller LB; Olson DP; Pedersen N; Ploug M
Cell Differ Dev; 1990 Dec; 32(3):247-53. PubMed ID: 1965953
[No Abstract] [Full Text] [Related]
3. Prourokinase activation on the surface of human rhabdomyosarcoma cells: localization and inactivation of newly formed urokinase-type plasminogen activator by recombinant class 2 plasminogen activator inhibitor.
Pöllänen J; Vaheri A; Tapiovaara H; Riley E; Bertram K; Woodrow G; Stephens RW
Proc Natl Acad Sci U S A; 1990 Mar; 87(6):2230-4. PubMed ID: 2138329
[TBL] [Abstract][Full Text] [Related]
4. Plasminogen activators and angiogenesis.
Mignatti P; Rifkin DB
Curr Top Microbiol Immunol; 1996; 213 ( Pt 1)():33-50. PubMed ID: 8814993
[No Abstract] [Full Text] [Related]
5. Plasminogen activation on tumor cell surface and its involvement in human leukemia.
Tapiovaara H; Alitalo R; Vaheri A
Adv Cancer Res; 1996; 69():101-33. PubMed ID: 8791680
[No Abstract] [Full Text] [Related]
6. Kinetic analysis of the effects of glycosaminoglycans and lipoproteins on urokinase-mediated plasminogen activation.
Edelberg JM; Weissler M; Pizzo SV
Biochem J; 1991 Jun; 276 ( Pt 3)(Pt 3):785-91. PubMed ID: 1829607
[TBL] [Abstract][Full Text] [Related]
7. Interferons and retinoids enhance and dexamethasone suppresses urokinase-mediated plasminogen activation in promyelocytic leukemia cells.
Mustjoki S; Tapiovaara H; Sirén V; Vaheri A
Leukemia; 1998 Feb; 12(2):164-74. PubMed ID: 9519778
[TBL] [Abstract][Full Text] [Related]
8. Enhanced activation of prourokinase by human RC2A leukemia cells.
Tapiovaara H; Vaheri A; Alitalo R; Sim PS; Woodrow G; Stephens RW
Semin Thromb Hemost; 1991 Jul; 17(3):251-61. PubMed ID: 1665587
[No Abstract] [Full Text] [Related]
9. Cellular receptors in the regulation of plasmin generation.
Hajjar KA
Thromb Haemost; 1995 Jul; 74(1):294-301. PubMed ID: 8578475
[TBL] [Abstract][Full Text] [Related]
10. Urokinase-dependent proteolysis in cultured colon cancer is directed by its receptor.
Hollas W; Boyd D
Semin Thromb Hemost; 1991 Jul; 17(3):225-30. PubMed ID: 1665585
[No Abstract] [Full Text] [Related]
11. Generation of cell surface-bound plasmin by cell-associated urokinase-type or secreted tissue-type plasminogen activator: a key event in melanoma cell invasiveness in vitro.
Meissauer A; Kramer MD; Schirrmacher V; Brunner G
Exp Cell Res; 1992 Apr; 199(2):179-90. PubMed ID: 1531956
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of cancer cell urokinase plasminogen activator by its specific inhibitor PAI-2 and subsequent effects on extracellular matrix degradation.
Baker MS; Bleakley P; Woodrow GC; Doe WF
Cancer Res; 1990 Aug; 50(15):4676-84. PubMed ID: 2114945
[TBL] [Abstract][Full Text] [Related]
13. The role of the pericellular fibrinolytic system in angiogenesis.
Fukao H; Ueshima S; Okada K; Matsuo O
Jpn J Physiol; 1997 Apr; 47(2):161-71. PubMed ID: 9201545
[No Abstract] [Full Text] [Related]
14. Inhibition of plasminogen activation protects against ganglion cell loss in a mouse model of retinal damage.
Zhang X; Chaudhry A; Chintala SK
Mol Vis; 2003 Jun; 9():238-48. PubMed ID: 12813409
[TBL] [Abstract][Full Text] [Related]
15. Influence of urokinase on cell proliferation and invasion.
Binder BR
Blood Coagul Fibrinolysis; 1990 Dec; 1(6):717-20. PubMed ID: 1966799
[TBL] [Abstract][Full Text] [Related]
16. Activation of pro-urokinase and plasminogen on human sarcoma cells: a proteolytic system with surface-bound reactants.
Stephens RW; Pöllänen J; Tapiovaara H; Leung KC; Sim PS; Salonen EM; Rønne E; Behrendt N; Danø K; Vaheri A
J Cell Biol; 1989 May; 108(5):1987-95. PubMed ID: 2523891
[TBL] [Abstract][Full Text] [Related]
17. Plasminogen activator inhibitor-1 represses integrin- and vitronectin-mediated cell migration independently of its function as an inhibitor of plasminogen activation.
Kjøller L; Kanse SM; Kirkegaard T; Rodenburg KW; Rønne E; Goodman SL; Preissner KT; Ossowski L; Andreasen PA
Exp Cell Res; 1997 May; 232(2):420-9. PubMed ID: 9168821
[TBL] [Abstract][Full Text] [Related]
18. Fibrinolysis: the key to new pathogenetic mechanisms.
Zorio E; Gilabert-Estellés J; España F; Ramón LA; Cosín R; Estellés A
Curr Med Chem; 2008; 15(9):923-9. PubMed ID: 18473800
[TBL] [Abstract][Full Text] [Related]
19. Plasminogen activator system modulates invasive capacity and proliferation in prostatic tumor cells.
Festuccia C; Dolo V; Guerra F; Violini S; Muzi P; Pavan A; Bologna M
Clin Exp Metastasis; 1998 Aug; 16(6):513-28. PubMed ID: 9872599
[TBL] [Abstract][Full Text] [Related]
20. Thrombospondin-plasminogen interactions: modulation of plasmin generation.
Silverstein RL; Nachman RL
Semin Thromb Hemost; 1987 Jul; 13(3):335-42. PubMed ID: 2961063
[No Abstract] [Full Text] [Related]
[Next] [New Search]
